![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
ASSESSMENT OF JAK2V617F MUTATION FREQUENCY IN PATIENTS WITH POLYCYTHEMIA VERA CITY OF TABRIZ IN IRAN
Shahin Asadi*, Elham Alizadeh Milani, Ali Nazirzadeh, Vahid Ghorbani
ABSTRACT JAK2V617F mutation in the diagnosis and classification of myeloproliferative neoplasms has found wide application. In this study, JAK2V617F mutation frequency in patients with polycythemia vera Tabriz city were investigated. In this study, blood samples from 87 patients with polycythemia vera JAK2V617F mutation was investigated. DNA samples with proteinase k obtained from peripheral blood was extracted from buffy coat. After quality control, to assess the JAK2 mutation status of ARMS-PCR polymerase chain reaction with allele-specific primers were used. PCR products were electrophoresed on polyacrylamide gel electrophoresis and ethidium bromide staining were evaluated. Results: JAK2V617F mutation in 78.3% (58 patients) was observed myeloproliferative neoplasms. 58 patients with polycythemia vera, essential thrombocythemia, and 11 of 18 patients with primary myelofibrosis. Conclusion: This study showed that JAK2V617F mutation using allele-specific AST in patients with myeloproliferative neoplasms, speed and accuracy of diagnosis and the subsequent fate of patients with neoplasms Myeloproliferative promotes. Keywords: myeloproliferative neoplasms, mutation JAK2V617F, reaction ARMS-PCR. [Download Article] [Download Certifiate] |